Forget About Tech, AI is Going to Revolutionize Healthcare
We’ve previously noted that Artificial Intelligence (AI) is beginning to be integrated into healthcare/ pharmaceutical company operations.
Most notably, Nvidia (NVDA) has announced a partnership with drug giant Novo Nordisk (NVO) for new drug discovery programs.
Together, the pair (NVDA and NV) will plumb Novo Nordisk’s library of scientific literature to inform biomedical large language models intended to find correlations between genes, proteins and diseases…
On the discovery front, Novo Nordisk will use a range of NVIDIA offerings to build single-cell algorithms capable of predicting cellular responses to drug candidates and structures, as well as models that can build molecules with drug-like properties.
Source: FirstWord Pharma
Similarly, healthcare giant IQVIA (IQV) announced it will begin using NVDA to power AI-based lab assistants to help its scientists in the development of clinical trials.
IQVIA said its AI agents can support a range of applications, including identifying drug targets, reviewing clinical and scientific literature, analysing clinical data, assessing market opportunities and engaging with healthcare providers.
Source: FirstWord Pharma
These are not mere press releases either. An article in the Journal of American Medical Association (JAMA) Neurology notes that AI tools will soon be used to differentiate Parkinson’s from other, similar diseases that are extremely difficult to differentiate early on.
As one of the authors notes, Rizwan Akhtar, normally a physician would simply wait for the patient to continue developing symptoms… but this waiting uses up precious time if the patient turns out to have something other than Parkinsons; in those instances, the sooner the patient can enter into clinical trials or interventions, the better.
Enter AI.
Using a machine learning algorithm, researchers found that AI was able to distinguish Parkinson disease from three other, similar diseases between 94% and 98% of the time, compared to just 81% of the time for a clinician. As researchers noted, anything above 90% is considered outstanding… and AI was able to exceed that in every instance.
This is yet more evidence that the crossroads between AI and healthcare is going to produce extraordinary opportunities, both in terms of quality of life for patients and potential profits for investors.
On that note, we just published a new special investment report The AI Plays Your Broker Doesn’t Know About that details three “outside the box” investments designed to profit from AI. Best of all, Wall Street has no idea the potential here.
We are making just 99 copies available to the investing public. To pick up yours...
Best Regards
Graham Summers, MBA
Chief Market Strategist
Phoenix Capital Research